TLX:XETRTalanx AG Analysis
Data as of 2026-06-07 - not real-time
$9.30
Latest Price
8/10Risk
Risk Level: High
Executive Summary
TLX is trading at $9.30, below its 20‑day SMA of $9.94 and 50‑day SMA of $10.13, with a neutral RSI (~42) and a bearish MACD histogram, suggesting short‑term weakness. However, the stock exhibits a 30‑day volatility of over 50% and a beta above 1, highlighting heightened price swings.
Fundamentally, revenue surged 49% YoY to $804 M with a solid 47.5% gross margin, yet operating margins are thin (1.9%) and earnings are negative, driving a forward P/E of ~39.5 versus an industry average of 27.9. The balance sheet is strained, with a debt‑to‑equity ratio over 112 and cash covering less than a third of total debt.
Fundamentally, revenue surged 49% YoY to $804 M with a solid 47.5% gross margin, yet operating margins are thin (1.9%) and earnings are negative, driving a forward P/E of ~39.5 versus an industry average of 27.9. The balance sheet is strained, with a debt‑to‑equity ratio over 112 and cash covering less than a third of total debt.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages
- Bearish MACD and high volatility
- Negative earnings and heavy debt load
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth and 47.5% gross margin
- Phase 3 ZIRCON trial data indicating diagnostic market potential
- Strategic partnership with EDAP TMS expanding prostate imaging
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Broad pipeline of radiopharmaceuticals targeting multiple cancers
- Long‑term upside in precision‑medicine and imaging services
- Analyst consensus of strong‑buy with target price ~ $20.8
Key Metrics & Analysis
Financial Health
Revenue Growth49.30%
Profit Margin-0.89%
P/E Ratio39.5
ROE-1.86%
ROA1.15%
Debt/Equity112.45
P/B Ratio7.6
Op. Cash Flow$-17293000
Free Cash Flow$-36673500
Industry P/E27.9
Technical Analysis
TrendNeutral
RSI41.9
Support$8.69
Resistance$11.04
MA 20$9.94
MA 50$10.13
MA 200$9.22
MACDBearish
VolumeIncreasing
Fear & Greed Index83.02
Valuation
Target Price$20.84
Upside/Downside124.04%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.19
Volatility50.53%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.